MEI Pharma Announces Pricing Of Public Offering Of Common Stock

SAN DIEGO, Dec. 12, 2014  -- MEI Pharma, Inc. (MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that it has priced an underwritten public offering of 10,000,000 shares of its common stock at an offering price of $4.00 per share, for total gross proceeds (before underwriting discount and commissions and estimated expenses) of approximately $40 million. The Company has granted the underwriters a 30-day option to purchase up to 1,500,000 additional shares of its common stock. The offering is expected to close on December 17, 2014, subject to customary closing conditions.

The Company plans to use the net proceeds of the offering, together with other available funds, to progress the clinical development programs for Pracinostat in acute myeloid leukemia (AML) and for other general corporate purposes.

ChemoCentryx Announces Positive Results in Phase II Diabetic Nephropathy Trial With CCR2 Inhibitor CCX140

Primary Endpoint Achieved; Statistically Significant Reduction in Urinary Protein Over 52 Weeks
Improved Estimated Glomerular Filtration Rate Profile versus Standard of Care
Favorable Safety Profile for CCX140
Company to Host Conference Call and Webcast Today at 8:30a.m. ET

MOUNTAIN VIEW, Calif., Dec. 12, 2014  -- ChemoCentryx, Inc., (CCXI), a clinical-stage biopharmaceutical company focused on autoimmune diseases, inflammatory disorders and cancer, today announced positive top-line 52-week data from its Phase II clinical trial in diabetic nephropathy with CCX140, an inhibitor of the chemokine receptor known as CCR2.

Calithera Presents Novel Pharmacodynamic Assay Data Confirming Glutaminase Inhibition in Tumor Biopsy Samples From Patients Treated With CB-839

SOUTH SAN FRANCISCO, Calif., Dec. 10, 2014  -- Calithera Biosciences, Inc. (CALA), a clinical stage biotechnology company focused on the development of novel cancer agents, today announced results of studies with primary human breast tumors that support glutaminase as a potential target in triple negative breast cancer (TNBC). Using a novel pharmacodynamic assay designed to measure the extent of glutaminase inhibition in a single post-dose tumor biopsy sample, significant glutaminase inhibition was observed following oral administration of CB-839. These data were presented during the San Antonio Breast Cancer Symposium in San Antonio, Texas. Calithera is developing CB-839, a potent, selective and orally bioavailable glutaminase inhibitor that is currently in Phase I clinical trials in solid and hematological malignancies.